Title of Invention	BENZO[1,2,5] OXADIAZOLES, AND BENZO[1,2,5] THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS
Abstract	The present invention relates to novel benzo[l,2,5]oxadiazoles and benzo[l,2,5]thiadiazoles of formula (I) wherein X is O or S, Rl is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-<18>F-ethylamino)- thiazol-2-yl or a group of formula (a) wherein Y is CH or N, R2 is NHCH3, NH<11>CH3, N(CH3)<11>CH3, N(CH3)2, N(<11>CH3)2, NH(CH2)nF, NH(CH2)n<18>F, N(CH3)(CH2)nF, N(CH3)-(CH2)n <18>F, O-(CH2)nF, O-(CH2)n <18>F5 CONH(CH2)nF or CONH(CH2)n<18>F (n being in each case 2 to 4) and R3 is hydroxy, (Cl-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form; their preparation, their use as markers in diagnosis and compositions containing them.

Title of Invention

BENZO[1,2,5] OXADIAZOLES, AND BENZO[1,2,5] THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS

Abstract

The present invention relates to novel benzo[l,2,5]oxadiazoles and benzo[l,2,5]thiadiazoles of formula (I) wherein X is O or S, Rl is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-<18>F-ethylamino)- thiazol-2-yl or a group of formula (a) wherein Y is CH or N, R2 is NHCH3, NH<11>CH3, N(CH3)<11>CH3, N(CH3)2, N(<11>CH3)2, NH(CH2)nF, NH(CH2)n<18>F, N(CH3)(CH2)nF, N(CH3)-(CH2)n <18>F, O-(CH2)nF, O-(CH2)n <18>F5 CONH(CH2)nF or CONH(CH2)n<18>F (n being in each case 2 to 4) and R3 is hydroxy, (Cl-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form; their preparation, their use as markers in diagnosis and compositions containing them.

Full Text	BenzoM.2,51oxadiazotes and Benzof1,2,5"lthiadiazoles useful as Histopatholoqical Staining Agents, Imaging Agents and Biomarkers The present invention relates to novel benzo[1,2,5]oxadiazoies and benzo[1,2,5]thiadiazoles, their preparation, their use as markers and compositions containing them. More particularly the invention provides a compound of formula I wherein X is 0 or S, R, is 5-(2-fluoro-ethylaminoMhiazol-2-yl, 5-(2-18F-ethyIamino)-thiazol-2-yl or a group of formula (a) wherein Y is CH or N, R2 is NHCH3, NH11CH3, N(CH3)11CH3, N(CH3)2) N(11CH3)2, NH(CH2)nF, NH(CH2)n18F, N(CH3MCH2)nF, N(CH3MCH2)n18F, 0-(CH2)nF, O-(CH2)n18F, CONH(CH2)nF or CONH(CH2)n18F (n being in each case 2 to 4) and R3 is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or add addition salt form. The term (C1-4)a!koxy as used herein relates to a radical comprising an alkyl moiety with from and including 1 up to and including 4 C atoms and is linear or branched; preferably (C1-4)alkoxy is methoxy, ethoxy or n-propoxy. Natural occurring carbon consists of the isotopes 12C (98.90%), 13C (1.10 %) and traces of 14C. The term "11C" denotes that a higher ratio of the respective carbon atoms in a radical or moiety correspond to 11C isotopes as compared to natural occurring carbon, especially a radical or moiety wherein at least 25 %, preferably at least 90 %, more preferably at least 95 %, of the carbon atoms are 11C isotopes. The 11C isotope can be prepared by methods known as such. Since the half-life period is short (about 20 min), the isotope needs to be freshly prepared shortly before usage in reagents by employment of a cyclotron. The methylation reaction using 11C-methyl iodide is the most used reaction in 11C labelling synthesis. A suitable method is based on the reduction of trapped 11C-carbon dioxide with lithium aluminumhydride in tetrahydrofuran, followed by removal of solvent. Hydroiodic acid is added and the formed 11C-methyl iodide distilled in a stream of nitrogen gas to the reaction flask. Natural occurring fluorine consists of the isotope 19F (100 %). The term "18F" denotes that a higher ratio of the respective fluorine atoms in a radical or moiety correspond to 18F isotope as compared to natural occurring fluorine, especially a radical or moiety wherein at least 25 %, preferably at least 90 %, more preferably at least 95 %, of the fluorine atoms are 18F isotopes. The 18F isotope can be prepared by methods known as such. Since the half-life period is short (about 110 min), the isotope needs to be freshly prepared shortly before usage in reagents by employment of a cyclotron. 1GF can be obtained, e.g., by irradiating a target containing 180-H20 with a proton beam, in a cyclotron. In this process, 18F is obtained from the 180(p,n) 18F nuclear reaction and used immediately to generate final radiomarkers as described, e.g. in "Fundamentals of Positron Emission tomography and Applications in Preclinical Drug Development", Simon R Cherry, J Clin Pharmacol 2001; 41:482-491, and the references cited therein, which publication is included in the present patent filing by reference. For diagnostic purposes, those compounds of formula I are preferred comprising 11C or 18F. in a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, comprising the steps of a) for the production of a compound of formula I which contains no 11C or 18F atom, reacting a compound of formula II wherein X is as defined above and Hal is CI, Br or I, with 5-(2-fluoro-ethy!amino)thiazoIyl-2-boronic acid or a compound of formula II) wherein Y and R3 are as defined above and R2 is a group R2 as defined above which contains no 11C or 18F atom, or b) for the production of a compound of formula I wherein R, is 5-(2-1BF-ethylarnino)-thiazol-2-yl, reacting a compound of formula I wherein Ri is 5-(2-mesyioxy-ethylarninoHhiazoI-2-yl or 5-(24osyloxy-ethylamino)-thiazol-2-yl with 18Fe, or c) for the production of a compound of formula I wherein R2 is NH11CH3l N(CH3)11CH3 or N(11CH3)£f reacting a compound of formula I wherein R2 is NH2 or NHCH3 with 11CH3I, or d) for the production of a compound of formula I wherein R2 is NH(CH2)n18F, N(CH3)- (CH2)n18F, 0-(CH2)n18F or CONH(CH2)n18F, reacting a compound of formula I wherein R2 is, respectively, NH(CH2)nOTs or NH(CH2)nOMs, N(CH3HCH2)nOTs or N(CH3HCH2)n- OMs, 0-(CH2)nOTs or ©-(CH^-OF^s, or CONH(CH2)nOTs or CONHCCH^OMs, with iBpe and recovering the resulting compound of formula I in free base form or in form of an acid addition salt. The reaction described under a) can be effected according to known methods, for example as described in Example 1. Alternatively to process a), conventional methods can be used for the production of compounds of formula I which contain no 11C or 18F atom, for example as described in Examples 4, 7 and 13 to 25. The reactions described under b)f c) and d) can be effected according to conventional methods. Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures. Acid addition salts may be produced from the free bases in known manner, and vice-versa. The agents of the invention have a high affinity to li-amyloid deposits, especially extracellular ft-amyloid deposits, and bind to these deposits by means of physical or chemical interaction. Hence, the agents of the invention can be used in the therapy or diagnosis of diseases wherein such S-amyloid deposits are observed, such as Alzheimer's Disease. Preferably, the agents of the invention are used in diagnosis. In particular, compounds of formula I in free base or acid addition salt form, hereinafter referred to as agents of the invention, exhibit valuable properties as histopathological staining agents, imaging agents and/or biomarkers, hereinafter "markers". More particularly, the agents of the invention are useful as markers for labeling pathological structures such as extracellular IS-amyloid deposits, e.g. in the brain of patients with Alzheimer's disease (see Example 26). The agents of the invention are therefore useful for the early diagnosis and prevention of Alzheimer's disease and for monitoring the effectiveness of therapeutic treatments of Alzheimer's disease. The advantages of assessing amyloid deposits in vivo and non-invasively using markers capable of labeling these structures have been reported e.g. in WO 00/10614, which is incorporated herein by reference. In accordance with the above, the present invention provides a composition for labeling histopathologic^! structures in vivo or in vitro, comprising an agent of the invention. In a further aspect, the present invention provides a method for labeling histopathological structures in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention. Said brain tissue comprises for example B-amyloid deposits. Contacting the brain tissue with the agent of the invention is for example effected by administering the agent of the invention to a patient, e.g. a patient with Alzheimer's disease. The method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure. If the agent of the invention is a non-radioactive compound of formula I, said further step may be effected by observing the target structure using fluorescence microscopy. If the agent of the invention is a radioactive compound of formula I, said further step may be effected by observing the target structure using positron emission tomography (PET). Labeling histopathological structures in vitro is effected, for example, for detecting histopathological hallmarks of Alzheimer's disease. Labeling histopathological structures in vivo is effected, for example, for diagnosing Alzheimer's disease in a patient or for monitoring the effectiveness of a therapeutic treatment of Alzheimer's disease. In further aspects, the present invention relates to • the use of a compound of formula I for the manufacture of a preparation for the treatment or diagnosis of Alzheimer's disease; • a package comprising a compound of formula I wherein R2 is NH2 or NHCH3 together with instructions for the production of a compound of formula ! wherein R2 is acid. After stirring at reflux for 18h, the reaction mixture is cooled to room temperature and extracted with ethyl acetate and water. The organic phases are combined, dried with magnesium sulfate, filtered and evaporated. The residue is column chromatographed (hexane, then hexane/ethyl acetate 8:1 then 5:1) to yield the desired product as a yeliow solid. MS(ES+): 240 (M+1). 1H-NMR (CDC!3, 400 MHz): delta (ppm) = 7.83 (d, Harom); 7.82 (s, Haram); 7.73 (d, Harom); 7.58, 6.81 (2d, 2x2Harom); 3.05 (s, 2Me). The following compounds of examples 2 to 6 can be prepared according to the same procedure: Example 2: (4-BenzoH ,2t51thiadiazol-4-vl-phenv!)-dimethvl-amine Starting from 4-iodo-benzo[1,2,5]thiadiazole and 4-(dimethylamino)phenylboronic acid. Orange powder. MS(ES+): 256 (M+1). Example 3: (4-Benzof1,2,51oxadiazol-4-vl-phenvl')-dimethvl-amine Starting from 4-chloro-benzo[1,2,5]oxadiazole and 4-(dimethylamino)phenyIboronic acid-Orange powder. MS(ES+): 240 (M+1). Example 4: (3-Benzon,2,51oxadiazot-5-vl-phenvl)-methvl-amine Starting from 5-benzo[1,2,5]oxadiazoleboronicacid and (S-bromo-phenyl)-methyl-amine. Yellow powder. MS(ES+): 226 (M+1). Example 5: 5-r4-(2-Fluoro-ethoxY)-phenyn-benzori,2,51oxadiazole Starting from 5-benzo[1,2,5]oxadiazoleboronicacid and 1 -bromo-4-(2-fluoro-ethoxy)-benzene. Yellow-beige powder. MS(ES+): 259 (M+1). Example 6: (3-Benzon ,2,51oxadiazol-5-vl-phenvlVdimethvl-amine Starting from 5-benzo[1,2,5]oxadiazoIeboronic acid and (3-bromo-phenyI)-dimethyl-amine. Orange-yellow powder. MS(ES+): 240 (M+1). Example 7: (2-Benzori,2,51oxadiazol-5-vl-phenyl) 523 mg (1.65 eq.) bis(pinaco!ato)diboran, 552 mg (4.5 eq.) potassium acetate and 51 mg (0.01 eq.) PdCI(dppf)-CH2CI2 are added to a solution of 373 mg 5-bromo-benzo[1,2,5]oxa-diazole in 8 mL DMF and heated to 80°C under continuous stirring for 6 hours. 662 mg (5 eq.) sodium carbonate in 3.3 mL water are added together with 500 mg (1 eq.) 2-bromo-N,N-dimethylaniline and 51 mg (0.01 eq.) PdCI(dppf)-CH2CI2 to the reaction mixture, which is stirred for another 18 hours at 80°C, cooled to room temperature and extracted with ethyl acetate and water. The combined organic phases are washed with brine, dried over magnesium sulfate and evaporated. The residue is column chromatographed (hexane, then hexane/ethyl acetate 8:1) to yield the desired product as an orange resin. MS(ES+): 240 (M+1). 1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.77 (s, Harom); 7.71, 7.69 (2d, 2Haram); 7.25, 7.03 (2m, 2x2Harom); 2.53 (s, 2Me). The following compounds of Examples 8 to 12 are synthesized according to the same procedure: Example 8: (2-Benzon.2.51thiadiazol-5-vl-phenvl)-dimethvl-amine Starting from 5-bromo-benzo[1,2,5]thiadiazoIe and 2-bromo-NlN-dimethylaniIine. Orange resin. MS(ES+): 256 (M+1). Example 9: (3-Benzon,2,51oxadiazol-4-vl-phenvl)-methvl-amine. Starting from 5-chloro-benzo[1,2,5]oxadiazole and (3-bromo-phenyl)-methyl-amine. Yellow powder. MS(ES+): 226 (M+1). The starting material is obtained as follows: (3-Bromo-phenvO-methvl-amine 2g (11.6 mmol) 3-Bromoaniline is dissolved in 15 mL DMF and treated with 716 mg (1.1 eq.) KOH and 0.722 mL (1 eq.) iodomethane under continuous stirring at room temperature for 20 hours. The reaction mixture is extracted with ethyl acetate and water, the combined organic phases are washed with brine and dried with sodium sulfate and evaporated to dryness. The residue is column chromatographed (ethyl acetate/petroleum ether 2:5) to yield after evaporation the desired product as a yellow oil. Example 10: 4-r4-(2-Fluoro-ethoxy)-phenvn-benzori ,2,51oxadiazole. Starting from 4-chloro-benzo[1,2,5]oxadiazoie and 1-bromo-4-(2-fluoro-ethoxy)-benzene. Yellow crystals. MS(ES+): 259 (M+1). Example 11: 5-BenzoH ,2,51oxadiazol-5-vl-N-(2-fluoroethvlVnicotinamide Starting from 5-bromo-benzo[1,2,5]oxadiazole and 5-bromo-N-(2-fluoro-ethyI)-nicotinamide. Beige powder. MS(ES-): 285 (M-1). The starting material is obtained as follows: 5-Bromo-N-(2-fluoro-ethvlVnia>tinamide 2.03 g (10 mmol) 5-bromonicotinic acid, 1 g (1 eq.) 2-fluoroethylamine, 2.31 g (1.2 eq.) EDC.HCI, 123 mg (0.1 eq.) DMAP and 5.6 mL (4 eq.) triethylamine are stirred in 60 mL dichloromethane for 20 hours at room temperature. The reaction mixture is extracted with dichloromethane and water, the combined organic phases are washed with brine, dried with sodium sulfate and evaporated. The residue is triturated in diethylether and hexane to yield after filtration the desired product as a white powder. MS(ES+): 347 and 349 (M+1). Example 12: 4-Benzof1.2.51oxadiazol-5-vl-N-(2-fluoro-ethvlVnicotinamide. Starting from 4-chloro-benzo[1,2,5]oxadiazoIe and 5-bromo-N-(2-fluoro-ethyl)-nicotinamide. Beige powder. MS(ES-): 285 (M-1). Example 13: (4-Benzon,2,51oxadiazol-5-vl-phenvlVmethvl-amine 510 mg (1.57 eq.) (4-benzoI1,2,5]oxadiazol-5-yl-phenyl)-methyl-carbamic acid tert-butyl ester are dissolved in 10 mL dichloromethane, treated with 0.126 mL (1.05 eq.) trifluoroacetic acid and stirred overnight at room temperature. The reaction mixture is evaporated and the residue column chromatographed (hexane, hexane/ethyl acetate 4:1 then 3:1) to yield the desired product as an orange solid. MS(ES+): 226 (M+1). 1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.82 (d. Harom); 7.81 (s, Harom), 7.71 (d, Harom); 7.54, 6.72 (2d, 2x2HarDnl); 2.92 (s, Me). The starting material is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5]oxadiazole and (4-bromo-phenyI)-methyl-carbamic acid tert-butyl ester, as a yellow powder. 1H-NMR (CDCI3, 400 MHz): delta (ppm) = 7.84 (s, Harom); 7.82, 7.63 (2d, 2Harom); 7.54, 7.18 (2d, 2x2 Harom); 3.26 (s, Me); 1.43 (s, tBu). The following compounds of example 14 to 16 are prepared according to the same procedure: Example 14: (4-BenzoH ,2.57thiadiazoN5-vl-phenvlVmethvl-amine. Starting from (4-benzo[1,2,5]thiadiazol-5-yl-phenyl)-methyI-carbamic acid tert-butyl ester. MS(ES+):242(M+1). The starting compound is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5JthiadiazoIe and (4-bromo-phenyl)-methyl-carbamic acid tert-butyl ester, as a yellow powder. 1H-NMR (CDCI3J 400 MHz): delta (ppm) = 8.08 (s. Harom); 7.98, 7.80 (2d, 2Harom); 7.60, 7.33 (2d, 2x2 Harom); 3.26 (s, Me); 1.43 (sf tBu). The starting material is obtained as follows: a) (4-Bromo-phenvl)-methvl-carbamic acid tert-butvl ester 0.263 mL (1.1 eq.) iodomethane are added dropwise at room temperature to a stirred suspension of 1.1 g (4 mmol) (4-bromo-phenyI)-carbamic acid tert-butyl ester and 2 g (1.6 eq.) cesium carbonate in 15 mL DMF. After stirring for an additional 18 hours, the reaction mixture is extracted with water/ethyl acetate and the combined organic phases are washed with brine, dried over magnesium sulfate and evaporated to yield the desired product as a colorless oil, which is used without further purification. b) (4-Bromo-phenvl)-carbamic acid tert-butvl ester 2 mL (1.2 eq.) Triethylamine are added to a solution of 2g (11.6 mmol) p-bromo-aniline in 25 mL THF. The reaction mixture is cooled to 0°C and treated with 2.66 g (1.05 eq.) Boc20 under continuous stirring, then allowed to reach 20°C, stirred for an additional 20 hours and extracted with water/ethyl acetate. The combined organic phases are washed with brine, dried over magnesium sulfate and evaporated. The residue is column chromatographed (hexane, hexane/ethyl acetate 7:1 then 4:1) to yield after evaporation and recrystallization from hexane the desired product as a white powder. Example 15: (4-BenzoH ,2.51oxadiazol-5-vi-3-methoxvph8nvl)-methvl-g.mine Starting from (4-Benzo[1,2J5]oxadiazol-5-yl-3-methoxy-phenyI)-methykcarbamicacid tert-butyl ester. 1H-NMR (CD3OD, 400 MHz): delta (ppm) = 7.78 (m, 3Harom); 7.25 (d, Harom); 6.38 (m, Harom); 6.36 (m, Harom); 3.83 (s, Me); 2.84 (s, Me). The starting compound is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5]oxadiazole and (4-bromo-3-methoxy-phenyI)«methyI»carbamic acid tert-butyl ester, as a yellow powder. MS(ES+): 378 (M+23). The starting material is obtained as follows: (4-Bromo-3-methoxv-phenvlVmethyl-carbamic acid tert-butvl ester 0.5 mL (1.1 eq.) iodomethane are added dropwise at room temperature to a stirred suspension of 2 g (6.6 mmol) (4-benzo[1,2,5]oxadiazol-5-yl-3-methoxy-phenyl)-methyI-carbamic acid tert-butyi ester and 3.2 g (1.5 eq.) cesium carbonate in 50 mL DMF. After stirring for an additional 17 hours, the reaction mixture is extracted with water/ethyl acetate and the combined organic phases are washed with brine, dried over magnesium sulfate and evaporated to yield the desired product as a yellow oil, which is used without further purification. Example 16: (4-Benzof1,2,51oxadiazol-5-vl-3-methoxv-phenvl)-f2-fluoro-ethvl)-amine Starting from (4-benzo[1,2,5]oxadiazol-5-yl«3-methoxy»phenyl)-(2-fluoro-ethyl)-carbamic acid tert-butyl ester. 1H-NMR (CD3OD, 400 MHz): delta (ppm) = 7.78-7.84 (m, 3^™); 7.26 (d, Harom); 6.44 (s, Ha™); 6.40 (d, Harom); 4.68 (t, CH2F); 4.58 (tf CHbF); 3.82 (s, Me); 3.55 (t, Chysi); 3.46 (t, CHoN). The starting compound is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5]oxadiazole and (4-bromo-3-methoxy-phenyl)-(2-fluoro-ethyl)-carbamic acid tert-butyl ester, as a yellow glass. MS(ES+): 410 (M+23). The starting material is obtained as follows: (4-Bromo-3-methox\^phenvl)-methvl-carbamic acid tert-butyl ester 0.63 mL (1.25 eq.) 1-bromo-2-fIuoroethane are added at room temperature to a stirred suspension of 2 g (6.6 mmol) (4-benzo[1f2,5]oxadiazol-5-yl-3-methox>'-phenyl)-methyI-carbamic acid tert-butyl ester and 3.2 g (1.5 eq.) cesium carbonate in 50 mL DMF. After stirring for 12 hours at 50 to 55 CC, the reaction mixture is cooled to rt. And extracted with water/ethyl acetate. The combined organic phases are washed with brine, dried over magnesium sulfate and evaporated to yield the desired product as a yellow oil, which is used without further purification. Example 17 (4-BenzoH .2.51oxadiazol-5-vl-phenvl)-(2-fluoro-ethvlVmethyl-amine 220 mg (0.98 mmol) (4-benzo[1,2,5]oxadiazol-5-yl-phenyl)-methyl-amine are dissolved in 5 mL DMF, treated with 1.9 g (6 eq.) cesium carbonate, 320 mg (2 eq.) potassium iodide and 0.364 mL (5 eq.) 1-bromo-2-fluoroethane, and stirred for 20 hours at 50°C. The reaction mixture is extracted with water and ethyl acetate, the combined organic phases are washed with water and brine, dried over magnesium sulfate and evaporated. The residue is column chromatographed (gradient from hexane to ethyl acetate) to yield the desired product as an orange powder. 1H-NMR (CDCIs. 400 MHz): delta (ppm) = 7.77 (d, Harom); 7.75 (s, Harom); 7.65 (d, Har0m); 7.51, 6.75 (2d, 2x2Harom); 4.57, 3.67 (2m, 2CH2); 3.04 (s, Me), Example 18: 543-(2-FluoroethoxvVDhenvn-benzoH,2,51oxadiazole 600 mg (2.83 mmol) 3-benzo[1,2,5]oxadiazoI-5-yl-phenol are dissolved in 15 mL DMF and stirred for 20 hours at room temperature in the presence of 1.15 g (1.25 eq.) cesium carbonate and 0.264 mL 1-bromo-2-fluoroethane. The reaction mixture is extracted with water and ethyl acetate, the combined organic phases are washed with water and brine, dried with magnesium sulfate and evaporated to dryness. The residue is column chromatographed (gradient from hexane to hexane/ethyl acetate 3:2) to yield the desired product as a pale yellow powder. MS(ES+): 259 (M+1). 1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.95 (s, Harom); 7.90 (d, Har0m); 7.70 (d, Hait)m); 7.42 (m, Haram); 7.27 (m, Harom); 7.22 (s, Harom); 7.04 (m, Harom); 4.80, 4.31 (2m, 2CH2). The starting material 3-benzo[1,2,5]oxadiazoI-5-yl-phenoI is obtained according to the , procedure described in Example 1 starting from 5-bromo-benzo[1,2,53oxadiazole and 3-hydroxyphenylboronic acid, as a light yellow powder. 1H-NMR (CDCI3f 400 MHz): delta (ppm) = 7.94 (s, Haram); 7.92, 7.68 (2d, 2 Harom); 7.38 (t, Harom); 7.24 (d, Harom); 7.13 (s, Harom); 6.94 (d, Harorn); 4.93 (OH). Example 19: (2-BenzoH ,2,51oxadiazol-5-vl-thiazol-5-vlV(2-fluoro-ethvlVamine 53 mg (0.2 mmol) benzo[1,2,5]oxadiazoie-5-carboxylic acid [(2-fluoro-ethylcarbamoyl)-methyl]-amide and 97 mg (1.2 eq.) Lawesson's reagent are suspended in 20 mL toluene and heated to reflux for one hour. After cooling to room temperature, the reaction mixture is poured onto ice-water containing 2 mL of a saturated aqueous solution of sodium carbonate, then extracted with ethyl acetate. The combined organic phases are dried with sodium sulfate and evaporated to dryness. The residue is column chromatographed (petroleum ether/ethyl acetate 3:2) to yield after evaporation of the corresponding fractions the desired product as an orange powder. MS (ES+): 265 (M+1). 1H-NMR (CDCI3, 400 MHz): delta (ppm) = 8.12 (d. Harom); 7.95 (s, Harom); 7.82 (d, Harom); 7.04 (s, Hhrt); 4.70, 3.53 (2m, 2CH2). The starting materials were obtained as follows: a) Benzori,2,51oxadiazole-5-carboxvlic acid r(2-fluoro-ethvlcarbamovl)-methyll-amide 221 mg (1 mmol) [(benzo[1,2,5]oxadiazole-5-carbonyl)-amino]-aceticacid, 120 mg (1.2 eq.) 2-fluoroethylamine, 162 mg (1.2 eq.) HOBt and 230 mg (1.2 eq.) EDC.HCI are dissolved in 18 mL DMF and cooled to 5°C. 0.7 mL (4 eq.) Hunig's base are added under stirring, the reaction mixture is stirred for an additional 3 hours at room temperature then extracted with water and ethyl acetate. The combined organic phases are washed with brine, dried with sodium sulfate and evaporated to yield the desired product as a beige solid. MS(ES+):267(M+1). b) r(Benzori,2,51oxadiazole-5-carbonvl)-aminoVacetic acid 500 mg (2.13 mmol) [(benzo[1,2,5]oxadiazole-5-carbonyl)-amino]-acetic acid methyl ester are treated in 50 mL methanol with 6 mL (3 eq.) 1N KOH in methanol containing 10% water at room temperature for two hours, then cooled below 5°C and neutralized with 6 mL 1N aqueous HCI. The reaction mixture is extracted with ethyl acetate, the combined organic phases are washed with brine and dried with sodium sulfate, then evaporated to dryness to yield the desired product as a beige-pinkish powder. MS (ES-): 220 (M-1) c) r(Benzon,2,51oxadiazole-5-carbonvl)-amino1-acetic acid methyl ester 492 mg (3 mmol) benzo[1,2,5]oxadiazole-5-carboxy!ic acid 376 mg (1 eq.) glycine methyl ester hydrochloride, 486 mg (1.2 eq.) HOBt and 690 mg (1.2 eq.) EDC.HCI are dissolved in 20 mL DMF under argon and the reaction mixture is stirred at room temperature for 90 minutes after addition of 2 mL (4 eq.) HCinig's base. The reaction mixture is poured onto ice and brine, and extracted with ethyl acetate. The combined organic phases are dried with sodium sulfate and evaporated to yield the desired product as a beige powder. MS(ES+):236(M+1). Example 20: (4-Benzof1,2.51oxadiazol-5-vl-DhenvlH2-fluoro-ethvlVamine 391 mg (1 mmol) (4-ben2o[1,2,5]oxadia2ol-5-yl-phenyl)«(2-fluoro-ethyl)-carbamic acid benzyl ester are hydrogenated in the presence of Pd/C, the reaction mixture filtered through celite and evaporated to dryness. The residues is column chromatographed (dichloromethane/ petroleum ether 8:2) to yield the desired product as a yellow powder. MS(ES+): 258 (M+1). 1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.82 (d, Harom); 7.81 (s, Harom); 7.70 (d, Harom); 7.53 (m, 2Harom); 6.75 (m, 2Harom); 4.66, 3.51 (2m, 2CH2). The starting material is obtained according to the procedure described in Example 1 from 5-benzo[1,2,5]oxadiazoleboronic acid and (4-bromo-phenyl)-(2-fluoro-ethyl)-carbamic acid benzyl ester, as a light brown resin. MS(ES+): 392 (M+1). The starting compound can be synthesized as follows: a) f4-bromo-phenylVf2-fluoro-ethvlV-carbamic acid benzyl ester 2.9 g (6 mmol) toluene-4-methanesulfonic acid 2-[benzyloxycarbonyl-(4-bromo-phenyl)-amino]-ethyI ester are dissolved in 100 mL THF and stirred for 18 hours at room temperature after addition of a 1M solution of tetrabutyl-amrnonium fluoride in THF. The reaction mixture is poured onto ice and extracted v/ith tertbutyl-methyl ether and a saturated aqueous solution of sodium bicarbonate. The combined organic phases are washed with brine, dried with sodium sulfate and evaporated to dryness. The crude product is column chromatographed (petroleum ether/ethyl acetate 4:1) to yield 920 mg desired product as a yellow resin. MS(ES+):352(M+1). b) Toluene-4-methanesulfonic acid 2-rbenzvloxvcarbonvl-(4-bromo-phenvQ-aminoVethvl ester 1.3 g (6 mmol) 2-(4-bromo-phenylamino)-ethanol are dissolved in 150 mL toluene, treated with 0.93 mL (1.1 eq.) benzyloxycarbonylchloride and 6.3 mL (1.05 eq.) 1N aqueous sodium hydroxide solution. The reaction mixture is stirred at room temperature for 18 hours, then the aqueous phase separated and extracted with ethyl acetate and water. The combined organic phases are washed with water and brine, then evaporated to dryness to yield 2.1 g crude (4- bromo-phenyl)-(2-hydroxy-ethyl)-carbamic acid benzyl ester, which is reacted further without additional purification by dissolution in 100 mL dichloromethane, addition of 5 mL (excess) pyridine, cooling to 5°C and dropwise addition in 10 minutes of 2.45 g p-toluenesulfonic acid anhydride in 20 mL dichloromethane. The reaction mixture is stirred an additional 2 hours at room temperature and poured onto ice, then extracted at 10°C with dichloromethane and an aqueous solution of sodium bicarbonate. The combined organic phases are dried with sodium sulfate and evaporated to yield the desired product as a light brownish resin, which is used without further purification. Example 21: (4-BenzoM ,2,51oxadiazol-5-vl-2-nitro-phenvn-methvl-amine 140 mg (0.62 mmol) (4-benzo[1,2,5]oxadiazol-5-yl-phenyI)-methyl-amine are stirred at 0°C in 2 mL concentrated sulfuric acid, then treated with 66 mg (1.05 eq.) potassium nitrate and stirred an additional 4 hours. The reaction mixture is poured onto ice, the precipitate filtered off, thoroughly washed with water and dried under high vacuum. The crude product is column chromatographed with ethyl acetate/petroleum ether 1:2 to yield after evaporation of the product-containing fraction the desired product as an orange solid. MS(ES-):269(M-i). 1H-NMR (CDCI3, 400 MHz): delta (ppm) ^ 8.55 (s, Harom); 8.22 (br.s, NH); 7.92 (d, Harom); 7.91 (s, i-UJ; 7.82 (d, HaTOm); 7.72 (d, Harom); 7.01 (d, Harom); 3.13 (s, Me). Example 22: 2-Benzof1.2,51oxadiazol*5-\d-5-methvlamino-Dhenol 100 mg (0.4 mmol) of (4-benzo[1,2,5]oxadiazoI-5-yI-3-methoxy-phenyl)-methyl-amine are stirred at - 10 to 0 °C in 1.3 mL of CH2CI2, then over 5 minutes treated with 1.3 mL AIBr3 (1.0 M solution in CH2Br2, 3 eq.) and stirred another 17 h under warming to rt. Then, the mixture is poured onto brine/ethyl acetate and the pH adjusted to 6 using NaHC03. Then the aqueous phase is extracted with ethyl acetate, the combined organic layers dried with sodium sulfate and concentrated. The crude product is column chromatographed with ethyl acetate/hexanes 1:1 to yield after evaporation of the product-containing fractions the desired product as a yellow solid. 1H-NMR (CD3OD, 400 MHz): defta (ppm) = 7.88-7.94 (m, 2Harom); 7.79 (d, Harom); 7.24 (d, Harom); 6.29 (d, Harom); 6.21 (m, H^); 2.81 (s, Me). Example 23: 2-BenzoM ,2,51oxadiazol-5-\ri-5-(2-fluoro~ethvlamino)-phenol 10 mg (0.03 mmol) of (4-benzo[1,2,5]oxadiazol«5-yl-3-methoxy-phenyl)-(2-fluoro-ethyl)-amine are dissolved in 0.3 mL acetic acid and 0.3 mL hydrobromic acid (33% in acetic acid) and stirred at 80 °C for 72h. Then the solvents are removed. The mixture of starting material and desired product can be separated by HPLC (20 to 100% CH3CN/H20 (6'), 100% CH3CN (1.5'), 100 to 20% CH3CN/H20 (0.5'): product elutes after 4.5'). MS(ES+): 274 (M+1). Example 24: (4-BenzoM ,2,51oxadiazol-5-vl-3-methox\^phenvl)-dimethyl-amine 200 mg (0.8 mmol) of (4-benzo[1,2,5]oxadiazol-5-yl-3-methoxy-phenyl)-methyl-arnine are stirred at 0 to 5 °C in 5 mL of DMF, then over 1 minute treated with 1 mL NaHMDS-solution (1.0 M, 1.25 eq.) and stirred another minute. Then, 0.5 mL (7.8 mmol, 10 eq.) of methyliodide is added and stirred 2 minutes under warming to rt. Then, the mixture is extracted with ethyl acetate/aqueous NaHC03 , the combined organic layers dried with sodium sulfate and concentrated. This yields the desired product as a reddish-yellow solid. 1H-NMR (CD3OD, 400 MKz): delta (ppm) = 7.80-7.84 (m, 2Harom); 7.36 (d, Harom); 6.50 (d, Harom); 6.45 (in, Harom); 3.90 (s, MeO); 3.08 (s, 2Me). Example 25: 2-Benzof1.2 140 mg (0.52 mmol) of (4-benzo[1,2,5]oxadiazol-5-yl-3-methoxy-phenyl)-dimethyl-amine are stirred at -10 to 0 °C in 1.7 mL of CH2CI2l then over 5 minutes treated with 1.7 mL AIBr3 (1.0 M solution in CH2Br2, 3.3 eq.) and stirred another 19 h under warming to rt. Then, the mixture is extracted with brine/ethyl acetate, the combined organic layers dried with sodium sulfate and concentrated. The crude product is column chromatographed with ethyl acetate/hexanes 1:4 to yield after evaporation of the product-containing fractions the desired product as a red solid. 1H-NMR (CD3OD, 400 MHz): delta (ppm) = 7.90-7.94 (m, 2Harom); 7.80 (d, Harom); 6.43 (d, Harom); 6.38 (m, Harom); 4.00 (s, 2Me). Example 26: Staining ofAPP23 mouse and human Alzheimer disease (AD) brain sections using an agent of the invention or Thioflavine S. Four-micrometer thick paraffin sections from an APP23 mouse at 26 months of age are deparaffinized in xylene and rehydrated. 10 mg of the compound are dissolved in 1 mL DMSO and diluted with deionized water 1:10. This staining solution is applied on sections for about 20 min. Section background is cleared by washing with 95% ethanol. Finally sections are dehydrated in 99% ethanol, cleared in xylene and mounted with Vectashield1m. Sections are investigated using fluorescence microscopy with the following filter combination: Excitation 450-490 nm, emission 510 nm. Twenty micrometer thick cryotom sections from a AD brain cortex are air dried and fixated in 4% PFA for 5 min. After washing in tap water sections are stained either with Thioflavine S or with the compound for 5 min and further processed as described above. The compound is dissolved in DMSO and diluted to a final concentration of 0.01 % with 50% Ethanol, Thioflavine S is dissolved in 50% Ethanol, final concentration is 0.01 %. Results: (These results do not apply to the compounds of Examples 4, 5, 11, 12 and 21, which are not fluorescent) 1) Staining of APP23 mice brain sections The agents of the invention strongly stain amyloid deposits and vascular deposits in brain sections ofAPP23 mice. 2) Staining of human AD brain sections: Brain sections taken from frontal cortex of AD patients are stained with the agents of the invention, and the results compared with a Thioflavine S stain. The agents of the invention intensely and selectively stain amyloid deposits. Claims 1. A compound of formula I wherein X is O or S, R^ is 5-(2-fluoro^thylamino)-thiazol-2-yI, 5-(2-™F-ethylamino)-thiazol-2-yl or a group of formula (a) wherein Y is CH or N, R2 is NHCH3, NH11CH3, N(CH3)11CH3, N(CH3)2\| N(11CHs)2l NH(CH2)nF, NH(CH2)n16F, N(CH3)-(CH2)nF, N(CH3)-(CH2)n18F, 0-(CH2)nF, O-(CH2)n18F, CONH(CH2)nF or CONH(CH2)nt3F (n being in each case 2 to 4) and R3 is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form. 2. A process for the production of a compound of formula I as defined in claim 1 and its salts, comprising the steps of a) for the production of a compound of formula I which contains no 11C or 18F atom, reacting a compound of formula ii wherein X is as defined in claim 1 and Hal is CI, Br or I, with 5-(2-fluoro-ethylamino)thiazolyi-2-boronic acid or a compound of formula III wherein Y and R3 are as defined above and R'2 is a group R2 as defined above which contains no 11C or 1BF atom, or b) for the production of a compound of formula I wherein R, is 5-(2-18F-ethylamino)-thiazoI-2-yl, reacting a compound of formula I wherein R-i is 5-(2-mesyloxy-ethylamino)-thiazoI-2-yl or 5-(2-tosyloxy^thylamino)-thiazoI-2-yI with 18Fe, or c) for the production of a compound of formula I wherein R2 is NH11CH3, N(CH3)11CH3 or N(11CH3)2, reacting a compound of formula I wherein R2 is NH2 or NHCH3 with 11CH3I, or d) for the production of a compound of formula I wherein R2 is NH(CH2)n18F, N(CH3)-(CH2)n16F, 0-(CH2)n16F or CONH(CH2)n1BF, reacting a compound of formula I wherein R2 is, respectively, NH(CH2)nOTs or NH(CH2)nOMs, N(CH3)-(CH2)nOTs or N(CH3)-(CH2)n-OMs, O-(CH2)nOTs or 0-(CH2)n-OMs, or CONH(CH2)nOTs or ONH(CH2)nOMs, with 1sFe, and recovering the resulting compound of formula I in free base form or in form of an acid addition salt 3. A composition for labeling histopathological structures in vitro or in vivo, comprising a compound of formula I as defined in claim 1, in free base or acid addition salt form. 4. A method for labeling histopathological structures in vitro or in vivo, comprising contacting brain tissue with a compound of formula I as defined in claim 1, in free base or acid addition salt form. 5. A method according to claim 4, for labeling E-amyloid deposits. 6. A method according to ciaim 4 or 5, comprising administering the compound of formula i to a patient. 7. A method according to any of claims 4 to 6, comprising the further step of determining whether the compound of formula I labeled the target structure. 8. A method according to claim 7, comprising observing the target structure labeled with a non-radioactive compound of formula I, using fluorescence microscopy. 9. A method according to claim 7, comprising observing the target structure labeled with a radioactive compound of formula I, using positron emission tomography (PET). 10. A method according to any one of claims 4 to 7, and 9 for diagnosing Alzheimer's disease. 11. A method according to claim 10, for monitoring the effectiveness of a therapeutic-treatment of Alzheimer's disease. 12. A method according to any of claims 4, 5, 7 and 8, for detecting histopathoiogical hallmarks of Alzheimer's disease. 13. The use of a compound of formula I according to claim 1 for the manufacture of a preparation for the treatment or diagnosis of Alzheimer's disease. 14. A package comprising a compound of formula I wherein R2 is NH2 or NHCHS together with instructions for the production of a compound of formula I wherein R2 is NH11CH3, N(CH3)11CH3 or N(11CH3)2 by reaction of the starting material with freshly prepared "CH3I. 15. A package comprising as starting material a compound of formula I wherein R2 is NH(CH2)nOTs, NH(CH2)nOMs, N(CH3KCH2)nOTs, N(CH3)-(CH2)nOMs, O-(CH2)nOTs, 0-(CH2)rrOMs, CONH(CH2)nOTs or ONH(CH2)nOMs, wherein OMs corresponds to mesylate and OTs to tosylate, together with instructions for the production of a compound of formula I wherein R2 is NH(CH2)n18F, N(CH3)-(CH2)n18F, 0-(CH2)n18F or CONH(CH2)n18F by a suitable reaction cascade of the starting material with 18F®.

Full Text

BenzoM.2,51oxadiazotes and Benzof1,2,5"lthiadiazoles useful as Histopatholoqical Staining Agents, Imaging Agents and Biomarkers
The present invention relates to novel benzo[1,2,5]oxadiazoies and benzo[1,2,5]thiadiazoles, their preparation, their use as markers and compositions containing them.
More particularly the invention provides a compound of formula I

wherein X is 0 or S, R, is 5-(2-fluoro-ethylaminoMhiazol-2-yl, 5-(2-18F-ethyIamino)-thiazol-2-yl or a group of formula (a)

wherein Y is CH or N, R2 is NHCH3, NH11CH3, N(CH3)11CH3, N(CH3)2) N(11CH3)2, NH(CH2)nF, NH(CH2)n18F, N(CH3MCH2)nF, N(CH3MCH2)n18F, 0-(CH2)nF, O-(CH2)n18F, CONH(CH2)nF or CONH(CH2)n18F (n being in each case 2 to 4) and R3 is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or add addition salt form.
The term (C1-4)a!koxy as used herein relates to a radical comprising an alkyl moiety with from and including 1 up to and including 4 C atoms and is linear or branched; preferably (C1-4)alkoxy is methoxy, ethoxy or n-propoxy.
Natural occurring carbon consists of the isotopes 12C (98.90%), 13C (1.10 %) and traces of 14C. The term "11C" denotes that a higher ratio of the respective carbon atoms in a radical or moiety correspond to 11C isotopes as compared to natural occurring carbon, especially a radical or moiety wherein at least 25 %, preferably at least 90 %, more preferably at least 95 %, of the carbon atoms are 11C isotopes.

The 11C isotope can be prepared by methods known as such. Since the half-life period is short (about 20 min), the isotope needs to be freshly prepared shortly before usage in reagents by employment of a cyclotron. The methylation reaction using 11C-methyl iodide is the most used reaction in 11C labelling synthesis. A suitable method is based on the reduction of trapped 11C-carbon dioxide with lithium aluminumhydride in tetrahydrofuran, followed by removal of solvent. Hydroiodic acid is added and the formed 11C-methyl iodide distilled in a stream of nitrogen gas to the reaction flask.
Natural occurring fluorine consists of the isotope 19F (100 %). The term "18F" denotes that a higher ratio of the respective fluorine atoms in a radical or moiety correspond to 18F isotope as compared to natural occurring fluorine, especially a radical or moiety wherein at least 25 %, preferably at least 90 %, more preferably at least 95 %, of the fluorine atoms are 18F isotopes.
The 18F isotope can be prepared by methods known as such. Since the half-life period is short (about 110 min), the isotope needs to be freshly prepared shortly before usage in reagents by employment of a cyclotron. 1GF can be obtained, e.g., by irradiating a target containing 180-H20 with a proton beam, in a cyclotron. In this process, 18F is obtained from the 180(p,n) 18F nuclear reaction and used immediately to generate final radiomarkers as described, e.g. in "Fundamentals of Positron Emission tomography and Applications in Preclinical Drug Development", Simon R Cherry, J Clin Pharmacol 2001; 41:482-491, and the references cited therein, which publication is included in the present patent filing by reference.
For diagnostic purposes, those compounds of formula I are preferred comprising 11C or 18F.
in a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, comprising the steps of
a) for the production of a compound of formula I which contains no 11C or 18F atom, reacting a compound of formula II

wherein X is as defined above and Hal is CI, Br or I, with 5-(2-fluoro-ethy!amino)thiazoIyl-2-boronic acid or a compound of formula II)

wherein Y and R3 are as defined above and R2 is a group R2 as defined above which contains no 11C or 18F atom, or
b) for the production of a compound of formula I wherein R, is 5-(2-1BF-ethylarnino)-thiazol-2-yl, reacting a compound of formula I wherein Ri is 5-(2-mesyioxy-ethylarninoHhiazoI-2-yl or 5-(24osyloxy-ethylamino)-thiazol-2-yl with 18Fe, or
c) for the production of a compound of formula I wherein R2 is NH11CH3l N(CH3)11CH3 or N(11CH3)£f reacting a compound of formula I wherein R2 is NH2 or NHCH3 with 11CH3I, or
d) for the production of a compound of formula I wherein R2 is NH(CH2)n18F, N(CH3)-
(CH2)n18F, 0-(CH2)n18F or CONH(CH2)n18F, reacting a compound of formula I wherein R2
is, respectively, NH(CH2)nOTs or NH(CH2)nOMs, N(CH3HCH2)nOTs or N(CH3HCH2)n-
OMs, 0-(CH2)nOTs or ©-(CH^-OF^s, or CONH(CH2)nOTs or CONHCCH^OMs, with iBpe
and recovering the resulting compound of formula I in free base form or in form of an acid addition salt.
The reaction described under a) can be effected according to known methods, for example as described in Example 1.

Alternatively to process a), conventional methods can be used for the production of compounds of formula I which contain no 11C or 18F atom, for example as described in Examples 4, 7 and 13 to 25.
The reactions described under b)f c) and d) can be effected according to conventional methods.
Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures.
Acid addition salts may be produced from the free bases in known manner, and vice-versa.
The agents of the invention have a high affinity to li-amyloid deposits, especially extracellular ft-amyloid deposits, and bind to these deposits by means of physical or chemical interaction. Hence, the agents of the invention can be used in the therapy or diagnosis of diseases wherein such S-amyloid deposits are observed, such as Alzheimer's Disease. Preferably, the agents of the invention are used in diagnosis.
In particular, compounds of formula I in free base or acid addition salt form, hereinafter referred to as agents of the invention, exhibit valuable properties as histopathological staining agents, imaging agents and/or biomarkers, hereinafter "markers".
More particularly, the agents of the invention are useful as markers for labeling pathological structures such as extracellular IS-amyloid deposits, e.g. in the brain of patients with Alzheimer's disease (see Example 26).
The agents of the invention are therefore useful for the early diagnosis and prevention of Alzheimer's disease and for monitoring the effectiveness of therapeutic treatments of
Alzheimer's disease.
The advantages of assessing amyloid deposits in vivo and non-invasively using markers capable of labeling these structures have been reported e.g. in WO 00/10614, which is incorporated herein by reference.

In accordance with the above, the present invention provides a composition for labeling histopathologic^! structures in vivo or in vitro, comprising an agent of the invention.
In a further aspect, the present invention provides a method for labeling histopathological structures in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention.
Said brain tissue comprises for example B-amyloid deposits.
Contacting the brain tissue with the agent of the invention is for example effected by administering the agent of the invention to a patient, e.g. a patient with Alzheimer's disease.
The method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure.
If the agent of the invention is a non-radioactive compound of formula I, said further step may be effected by observing the target structure using fluorescence microscopy.
If the agent of the invention is a radioactive compound of formula I, said further step may be effected by observing the target structure using positron emission tomography (PET).
Labeling histopathological structures in vitro is effected, for example, for detecting histopathological hallmarks of Alzheimer's disease.
Labeling histopathological structures in vivo is effected, for example, for diagnosing Alzheimer's disease in a patient or for monitoring the effectiveness of a therapeutic treatment of Alzheimer's disease.
In further aspects, the present invention relates to
• the use of a compound of formula I for the manufacture of a preparation for the treatment or diagnosis of Alzheimer's disease;
• a package comprising a compound of formula I wherein R2 is NH2 or NHCH3 together with instructions for the production of a compound of formula ! wherein R2 is

acid. After stirring at reflux for 18h, the reaction mixture is cooled to room temperature and extracted with ethyl acetate and water. The organic phases are combined, dried with magnesium sulfate, filtered and evaporated. The residue is column chromatographed (hexane, then hexane/ethyl acetate 8:1 then 5:1) to yield the desired product as a yeliow solid. MS(ES+): 240 (M+1).
1H-NMR (CDC!3, 400 MHz): delta (ppm) = 7.83 (d, Harom); 7.82 (s, Haram); 7.73 (d, Harom); 7.58, 6.81 (2d, 2x2Harom); 3.05 (s, 2Me).
The following compounds of examples 2 to 6 can be prepared according to the same
procedure:
Example 2: (4-BenzoH ,2t51thiadiazol-4-vl-phenv!)-dimethvl-amine
Starting from 4-iodo-benzo[1,2,5]thiadiazole and 4-(dimethylamino)phenylboronic acid. Orange powder. MS(ES+): 256 (M+1).
Example 3: (4-Benzof1,2,51oxadiazol-4-vl-phenvl')-dimethvl-amine
Starting from 4-chloro-benzo[1,2,5]oxadiazole and 4-(dimethylamino)phenyIboronic acid-Orange powder. MS(ES+): 240 (M+1).
Example 4: (3-Benzon,2,51oxadiazot-5-vl-phenvl)-methvl-amine
Starting from 5-benzo[1,2,5]oxadiazoleboronicacid and (S-bromo-phenyl)-methyl-amine. Yellow powder. MS(ES+): 226 (M+1).
Example 5: 5-r4-(2-Fluoro-ethoxY)-phenyn-benzori,2,51oxadiazole
Starting from 5-benzo[1,2,5]oxadiazoleboronicacid and 1 -bromo-4-(2-fluoro-ethoxy)-benzene. Yellow-beige powder. MS(ES+): 259 (M+1).
Example 6: (3-Benzon ,2,51oxadiazol-5-vl-phenvlVdimethvl-amine

Starting from 5-benzo[1,2,5]oxadiazoIeboronic acid and (3-bromo-phenyI)-dimethyl-amine. Orange-yellow powder. MS(ES+): 240 (M+1).
Example 7: (2-Benzori,2,51oxadiazol-5-vl-phenyl) 523 mg (1.65 eq.) bis(pinaco!ato)diboran, 552 mg (4.5 eq.) potassium acetate and 51 mg (0.01 eq.) PdCI(dppf)-CH2CI2 are added to a solution of 373 mg 5-bromo-benzo[1,2,5]oxa-diazole in 8 mL DMF and heated to 80°C under continuous stirring for 6 hours. 662 mg (5 eq.) sodium carbonate in 3.3 mL water are added together with 500 mg (1 eq.) 2-bromo-N,N-dimethylaniline and 51 mg (0.01 eq.) PdCI(dppf)-CH2CI2 to the reaction mixture, which is stirred for another 18 hours at 80°C, cooled to room temperature and extracted with ethyl acetate and water. The combined organic phases are washed with brine, dried over magnesium sulfate and evaporated. The residue is column chromatographed (hexane, then hexane/ethyl acetate 8:1) to yield the desired product as an orange resin. MS(ES+): 240 (M+1).
1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.77 (s, Harom); 7.71, 7.69 (2d, 2Haram); 7.25, 7.03 (2m, 2x2Harom); 2.53 (s, 2Me).
The following compounds of Examples 8 to 12 are synthesized according to the same procedure:
Example 8: (2-Benzon.2.51thiadiazol-5-vl-phenvl)-dimethvl-amine
Starting from 5-bromo-benzo[1,2,5]thiadiazoIe and 2-bromo-NlN-dimethylaniIine. Orange resin. MS(ES+): 256 (M+1).
Example 9: (3-Benzon,2,51oxadiazol-4-vl-phenvl)-methvl-amine.
Starting from 5-chloro-benzo[1,2,5]oxadiazole and (3-bromo-phenyl)-methyl-amine. Yellow
powder. MS(ES+): 226 (M+1).
The starting material is obtained as follows:
(3-Bromo-phenvO-methvl-amine

2g (11.6 mmol) 3-Bromoaniline is dissolved in 15 mL DMF and treated with 716 mg (1.1 eq.) KOH and 0.722 mL (1 eq.) iodomethane under continuous stirring at room temperature for 20 hours. The reaction mixture is extracted with ethyl acetate and water, the combined organic phases are washed with brine and dried with sodium sulfate and evaporated to dryness. The residue is column chromatographed (ethyl acetate/petroleum ether 2:5) to yield after evaporation the desired product as a yellow oil.
Example 10: 4-r4-(2-Fluoro-ethoxy)-phenvn-benzori ,2,51oxadiazole.
Starting from 4-chloro-benzo[1,2,5]oxadiazoie and 1-bromo-4-(2-fluoro-ethoxy)-benzene. Yellow crystals. MS(ES+): 259 (M+1).
Example 11: 5-BenzoH ,2,51oxadiazol-5-vl-N-(2-fluoro*ethvlVnicotinamide
Starting from 5-bromo-benzo[1,2,5]oxadiazole and 5-bromo-N-(2-fluoro-ethyI)-nicotinamide. Beige powder. MS(ES-): 285 (M-1).
The starting material is obtained as follows:
5-Bromo-N-(2-fluoro-ethvlVnia>tinamide
2.03 g (10 mmol) 5-bromonicotinic acid, 1 g (1 eq.) 2-fluoroethylamine, 2.31 g (1.2 eq.) EDC.HCI, 123 mg (0.1 eq.) DMAP and 5.6 mL (4 eq.) triethylamine are stirred in 60 mL dichloromethane for 20 hours at room temperature. The reaction mixture is extracted with dichloromethane and water, the combined organic phases are washed with brine, dried with sodium sulfate and evaporated. The residue is triturated in diethylether and hexane to yield after filtration the desired product as a white powder. MS(ES+): 347 and 349 (M+1).
Example 12: 4-Benzof1.2.51oxadiazol-5-vl-N-(2-fluoro-ethvlVnicotinamide.
Starting from 4-chloro-benzo[1,2,5]oxadiazoIe and 5-bromo-N-(2-fluoro-ethyl)-nicotinamide. Beige powder. MS(ES-): 285 (M-1).
Example 13: (4-Benzon,2,51oxadiazol-5-vl-phenvlVmethvl-amine

510 mg (1.57 eq.) (4-benzoI1,2,5]oxadiazol-5-yl-phenyl)-methyl-carbamic acid tert-butyl ester are dissolved in 10 mL dichloromethane, treated with 0.126 mL (1.05 eq.) trifluoroacetic acid and stirred overnight at room temperature. The reaction mixture is evaporated and the residue column chromatographed (hexane, hexane/ethyl acetate 4:1 then 3:1) to yield the desired product as an orange solid. MS(ES+): 226 (M+1).
1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.82 (d. Harom); 7.81 (s, Harom), 7.71 (d, Harom); 7.54, 6.72 (2d, 2x2HarDnl); 2.92 (s, Me).
The starting material is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5]oxadiazole and (4-bromo-phenyI)-methyl-carbamic acid tert-butyl ester, as a yellow powder.
1H-NMR (CDCI3, 400 MHz): delta (ppm) = 7.84 (s, Harom); 7.82, 7.63 (2d, 2Harom); 7.54, 7.18 (2d, 2x2 Harom); 3.26 (s, Me); 1.43 (s, tBu).
The following compounds of example 14 to 16 are prepared according to the same procedure:
Example 14: (4-BenzoH ,2.57thiadiazoN5-vl-phenvlVmethvl-amine.
Starting from (4-benzo[1,2,5]thiadiazol-5-yl-phenyl)-methyI-carbamic acid tert-butyl ester. MS(ES+):242(M+1).
The starting compound is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5JthiadiazoIe and (4-bromo-phenyl)-methyl-carbamic acid tert-butyl ester, as a yellow powder.
1H-NMR (CDCI3J 400 MHz): delta (ppm) = 8.08 (s. Harom); 7.98, 7.80 (2d, 2Harom); 7.60, 7.33 (2d, 2x2 Harom); 3.26 (s, Me); 1.43 (sf tBu).
The starting material is obtained as follows:
a) (4-Bromo-phenvl)-methvl-carbamic acid tert-butvl ester

0.263 mL (1.1 eq.) iodomethane are added dropwise at room temperature to a stirred suspension of 1.1 g (4 mmol) (4-bromo-phenyI)-carbamic acid tert-butyl ester and 2 g (1.6 eq.) cesium carbonate in 15 mL DMF. After stirring for an additional 18 hours, the reaction mixture is extracted with water/ethyl acetate and the combined organic phases are washed with brine, dried over magnesium sulfate and evaporated to yield the desired product as a colorless oil, which is used without further purification.
b) (4-Bromo-phenvl)-carbamic acid tert-butvl ester
2 mL (1.2 eq.) Triethylamine are added to a solution of 2g (11.6 mmol) p-bromo-aniline in 25 mL THF. The reaction mixture is cooled to 0°C and treated with 2.66 g (1.05 eq.) Boc20 under continuous stirring, then allowed to reach 20°C, stirred for an additional 20 hours and extracted with water/ethyl acetate. The combined organic phases are washed with brine, dried over magnesium sulfate and evaporated. The residue is column chromatographed (hexane, hexane/ethyl acetate 7:1 then 4:1) to yield after evaporation and recrystallization from hexane the desired product as a white powder.
Example 15: (4-BenzoH ,2.51oxadiazol-5-vi-3-methoxv*ph8nvl)-methvl-g.mine
Starting from (4-Benzo[1,2J5]oxadiazol-5-yl-3-methoxy-phenyI)-methykcarbamicacid tert-butyl ester.
1H-NMR (CD3OD, 400 MHz): delta (ppm) = 7.78 (m, 3Harom); 7.25 (d, Harom); 6.38 (m, Harom); 6.36 (m, Harom); 3.83 (s, Me); 2.84 (s, Me).
The starting compound is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5]oxadiazole and (4-bromo-3-methoxy-phenyI)«methyI»carbamic acid tert-butyl ester, as a yellow powder. MS(ES+): 378 (M+23).
The starting material is obtained as follows:
(4-Bromo-3-methoxv-phenvlVmethyl-carbamic acid tert-butvl ester 0.5 mL (1.1 eq.) iodomethane are added dropwise at room temperature to a stirred suspension of 2 g (6.6 mmol) (4-benzo[1,2,5]oxadiazol-5-yl-3-methoxy-phenyl)-methyI-carbamic acid tert-butyi ester and 3.2 g (1.5 eq.) cesium carbonate in 50 mL DMF. After

stirring for an additional 17 hours, the reaction mixture is extracted with water/ethyl acetate and the combined organic phases are washed with brine, dried over magnesium sulfate and evaporated to yield the desired product as a yellow oil, which is used without further
purification.
Example 16: (4-Benzof1,2,51oxadiazol-5-vl-3-methoxv-phenvl)-f2-fluoro-ethvl)-amine
Starting from (4-benzo[1,2,5]oxadiazol-5-yl«3-methoxy»phenyl)-(2-fluoro-ethyl)-carbamic acid tert-butyl ester.
1H-NMR (CD3OD, 400 MHz): delta (ppm) = 7.78-7.84 (m, 3^™); 7.26 (d, Harom); 6.44 (s, Ha™); 6.40 (d, Harom); 4.68 (t, CH2F); 4.58 (tf CHbF); 3.82 (s, Me); 3.55 (t, Chysi); 3.46 (t, CHoN).
The starting compound is obtained according to the procedure described in Example 7 from 5-bromo-benzo[1,2,5]oxadiazole and (4-bromo-3-methoxy-phenyl)-(2-fluoro-ethyl)-carbamic acid tert-butyl ester, as a yellow glass. MS(ES+): 410 (M+23).
The starting material is obtained as follows:
(4-Bromo-3-methox\^phenvl)-methvl-carbamic acid tert-butyl ester 0.63 mL (1.25 eq.) 1-bromo-2-fIuoroethane are added at room temperature to a stirred suspension of 2 g (6.6 mmol) (4-benzo[1f2,5]oxadiazol-5-yl-3-methox>'-phenyl)-methyI-carbamic acid tert-butyl ester and 3.2 g (1.5 eq.) cesium carbonate in 50 mL DMF. After stirring for 12 hours at 50 to 55 CC, the reaction mixture is cooled to rt. And extracted with water/ethyl acetate. The combined organic phases are washed with brine, dried over magnesium sulfate and evaporated to yield the desired product as a yellow oil, which is used without further purification.
Example 17 (4-BenzoH .2.51oxadiazol-5-vl-phenvl)-(2-fluoro-ethvlVmethyl-amine
220 mg (0.98 mmol) (4-benzo[1,2,5]oxadiazol-5-yl-phenyl)-methyl-amine are dissolved in 5 mL DMF, treated with 1.9 g (6 eq.) cesium carbonate, 320 mg (2 eq.) potassium iodide and 0.364 mL (5 eq.) 1-bromo-2-fluoroethane, and stirred for 20 hours at 50°C. The reaction

mixture is extracted with water and ethyl acetate, the combined organic phases are washed with water and brine, dried over magnesium sulfate and evaporated. The residue is column chromatographed (gradient from hexane to ethyl acetate) to yield the desired product as an orange powder.
1H-NMR (CDCIs. 400 MHz): delta (ppm) = 7.77 (d, Harom); 7.75 (s, Harom); 7.65 (d, Har0m); 7.51, 6.75 (2d, 2x2Harom); 4.57, 3.67 (2m, 2CH2); 3.04 (s, Me),
Example 18: 543-(2-FluoroethoxvVDhenvn-benzoH,2,51oxadiazole
600 mg (2.83 mmol) 3-benzo[1,2,5]oxadiazoI-5-yl-phenol are dissolved in 15 mL DMF and stirred for 20 hours at room temperature in the presence of 1.15 g (1.25 eq.) cesium carbonate and 0.264 mL 1-bromo-2-fluoroethane. The reaction mixture is extracted with water and ethyl acetate, the combined organic phases are washed with water and brine, dried with magnesium sulfate and evaporated to dryness. The residue is column chromatographed (gradient from hexane to hexane/ethyl acetate 3:2) to yield the desired product as a pale yellow powder. MS(ES+): 259 (M+1).
1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.95 (s, Harom); 7.90 (d, Har0m); 7.70 (d, Hait)m); 7.42 (m, Haram); 7.27 (m, Harom); 7.22 (s, Harom); 7.04 (m, Harom); 4.80, 4.31 (2m, 2CH2).
The starting material 3-benzo[1,2,5]oxadiazoI-5-yl-phenoI is obtained according to the , procedure described in Example 1 starting from 5-bromo-benzo[1,2,53oxadiazole and 3-hydroxyphenylboronic acid, as a light yellow powder.
1H-NMR (CDCI3f 400 MHz): delta (ppm) = 7.94 (s, Haram); 7.92, 7.68 (2d, 2 Harom); 7.38 (t, Harom); 7.24 (d, Harom); 7.13 (s, Harom); 6.94 (d, Harorn); 4.93 (OH).
Example 19: (2-BenzoH ,2,51oxadiazol-5-vl-thiazol-5-vlV(2-fluoro-ethvlVamine
53 mg (0.2 mmol) benzo[1,2,5]oxadiazoie-5-carboxylic acid [(2-fluoro-ethylcarbamoyl)-methyl]-amide and 97 mg (1.2 eq.) Lawesson's reagent are suspended in 20 mL toluene and heated to reflux for one hour. After cooling to room temperature, the reaction mixture is poured onto ice-water containing 2 mL of a saturated aqueous solution of sodium carbonate,

then extracted with ethyl acetate. The combined organic phases are dried with sodium sulfate and evaporated to dryness. The residue is column chromatographed (petroleum ether/ethyl acetate 3:2) to yield after evaporation of the corresponding fractions the desired product as an orange powder. MS (ES+): 265 (M+1).
1H-NMR (CDCI3, 400 MHz): delta (ppm) = 8.12 (d. Harom); 7.95 (s, Harom); 7.82 (d, Harom); 7.04 (s, Hhrt); 4.70, 3.53 (2m, 2CH2).
The starting materials were obtained as follows:
a) Benzori,2,51oxadiazole-5-carboxvlic acid r(2-fluoro-ethvlcarbamovl)-methyll-amide
221 mg (1 mmol) [(benzo[1,2,5]oxadiazole-5-carbonyl)-amino]-aceticacid, 120 mg (1.2 eq.) 2-fluoroethylamine, 162 mg (1.2 eq.) HOBt and 230 mg (1.2 eq.) EDC.HCI are dissolved in 18 mL DMF and cooled to 5°C. 0.7 mL (4 eq.) Hunig's base are added under stirring, the reaction mixture is stirred for an additional 3 hours at room temperature then extracted with water and ethyl acetate. The combined organic phases are washed with brine, dried with sodium sulfate and evaporated to yield the desired product as a beige solid. MS(ES+):267(M+1).
b) r(Benzori,2,51oxadiazole-5-carbonvl)-aminoVacetic acid
500 mg (2.13 mmol) [(benzo[1,2,5]oxadiazole-5-carbonyl)-amino]-acetic acid methyl ester are treated in 50 mL methanol with 6 mL (3 eq.) 1N KOH in methanol containing 10% water at room temperature for two hours, then cooled below 5°C and neutralized with 6 mL 1N aqueous HCI. The reaction mixture is extracted with ethyl acetate, the combined organic phases are washed with brine and dried with sodium sulfate, then evaporated to dryness to yield the desired product as a beige-pinkish powder. MS (ES-): 220 (M-1)
c) r(Benzon,2,51oxadiazole-5-carbonvl)-amino1-acetic acid methyl ester
492 mg (3 mmol) benzo[1,2,5]oxadiazole-5-carboxy!ic acid 376 mg (1 eq.) glycine methyl ester hydrochloride, 486 mg (1.2 eq.) HOBt and 690 mg (1.2 eq.) EDC.HCI are dissolved in 20 mL DMF under argon and the reaction mixture is stirred at room temperature for 90 minutes after addition of 2 mL (4 eq.) HCinig's base. The reaction mixture is poured onto ice and brine, and extracted with ethyl acetate. The combined organic phases are dried with sodium sulfate and evaporated to yield the desired product as a beige powder.

MS(ES+):236(M+1).
Example 20: (4-Benzof1,2.51oxadiazol-5-vl-DhenvlH2-fluoro-ethvlVamine
391 mg (1 mmol) (4-ben2o[1,2,5]oxadia2ol-5-yl-phenyl)«(2-fluoro-ethyl)-carbamic acid benzyl ester are hydrogenated in the presence of Pd/C, the reaction mixture filtered through celite and evaporated to dryness. The residues is column chromatographed (dichloromethane/ petroleum ether 8:2) to yield the desired product as a yellow powder. MS(ES+): 258 (M+1). 1H-NMR (CDCIs, 400 MHz): delta (ppm) = 7.82 (d, Harom); 7.81 (s, Harom); 7.70 (d, Harom); 7.53 (m, 2Harom); 6.75 (m, 2Harom); 4.66, 3.51 (2m, 2CH2).
The starting material is obtained according to the procedure described in Example 1 from 5-benzo[1,2,5]oxadiazoleboronic acid and (4-bromo-phenyl)-(2-fluoro-ethyl)-carbamic acid benzyl ester, as a light brown resin. MS(ES+): 392 (M+1).
The starting compound can be synthesized as follows:
a) f4-bromo-phenylVf2-fluoro-ethvlV-carbamic acid benzyl ester
2.9 g (6 mmol) toluene-4-methanesulfonic acid 2-[benzyloxycarbonyl-(4-bromo-phenyl)-amino]-ethyI ester are dissolved in 100 mL THF and stirred for 18 hours at room temperature after addition of a 1M solution of tetrabutyl-amrnonium fluoride in THF. The reaction mixture is poured onto ice and extracted v/ith tertbutyl-methyl ether and a saturated aqueous solution of sodium bicarbonate. The combined organic phases are washed with brine, dried with sodium sulfate and evaporated to dryness. The crude product is column chromatographed (petroleum ether/ethyl acetate 4:1) to yield 920 mg desired product as a yellow resin. MS(ES+):352(M+1).
b) Toluene-4-methanesulfonic acid 2-rbenzvloxvcarbonvl-(4-bromo-phenvQ-aminoVethvl
ester
1.3 g (6 mmol) 2-(4-bromo-phenylamino)-ethanol are dissolved in 150 mL toluene, treated with 0.93 mL (1.1 eq.) benzyloxycarbonylchloride and 6.3 mL (1.05 eq.) 1N aqueous sodium hydroxide solution. The reaction mixture is stirred at room temperature for 18 hours, then the aqueous phase separated and extracted with ethyl acetate and water. The combined organic phases are washed with water and brine, then evaporated to dryness to yield 2.1 g crude (4-

bromo-phenyl)-(2-hydroxy-ethyl)-carbamic acid benzyl ester, which is reacted further without additional purification by dissolution in 100 mL dichloromethane, addition of 5 mL (excess) pyridine, cooling to 5°C and dropwise addition in 10 minutes of 2.45 g p-toluenesulfonic acid anhydride in 20 mL dichloromethane. The reaction mixture is stirred an additional 2 hours at room temperature and poured onto ice, then extracted at 10°C with dichloromethane and an aqueous solution of sodium bicarbonate. The combined organic phases are dried with sodium sulfate and evaporated to yield the desired product as a light brownish resin, which is used without further purification.
Example 21: (4-BenzoM ,2,51oxadiazol-5-vl-2-nitro-phenvn-methvl-amine
140 mg (0.62 mmol) (4-benzo[1,2,5]oxadiazol-5-yl-phenyI)-methyl-amine are stirred at 0°C in 2 mL concentrated sulfuric acid, then treated with 66 mg (1.05 eq.) potassium nitrate and stirred an additional 4 hours. The reaction mixture is poured onto ice, the precipitate filtered off, thoroughly washed with water and dried under high vacuum. The crude product is column chromatographed with ethyl acetate/petroleum ether 1:2 to yield after evaporation of the product-containing fraction the desired product as an orange solid. MS(ES-):269(M-i).
1H-NMR (CDCI3, 400 MHz): delta (ppm) ^ 8.55 (s, Harom); 8.22 (br.s, NH); 7.92 (d, Harom); 7.91 (s, i-UJ; 7.82 (d, HaTOm); 7.72 (d, Harom); 7.01 (d, Harom); 3.13 (s, Me).
Example 22: 2-Benzof1.2,51oxadiazol*5-\d-5-methvlamino-Dhenol
100 mg (0.4 mmol) of (4-benzo[1,2,5]oxadiazoI-5-yI-3-methoxy-phenyl)-methyl-amine are stirred at - 10 to 0 °C in 1.3 mL of CH2CI2, then over 5 minutes treated with 1.3 mL AIBr3 (1.0 M solution in CH2Br2, 3 eq.) and stirred another 17 h under warming to rt. Then, the mixture is poured onto brine/ethyl acetate and the pH adjusted to 6 using NaHC03. Then the aqueous phase is extracted with ethyl acetate, the combined organic layers dried with sodium sulfate and concentrated. The crude product is column chromatographed with ethyl acetate/hexanes 1:1 to yield after evaporation of the product-containing fractions the desired product as a yellow solid.

1H-NMR (CD3OD, 400 MHz): defta (ppm) = 7.88-7.94 (m, 2Harom); 7.79 (d, Harom); 7.24 (d, Harom); 6.29 (d, Harom); 6.21 (m, H^); 2.81 (s, Me).
Example 23: 2-BenzoM ,2,51oxadiazol-5-\ri-5-(2-fluoro~ethvlamino)-phenol
10 mg (0.03 mmol) of (4-benzo[1,2,5]oxadiazol«5-yl-3-methoxy-phenyl)-(2-fluoro-ethyl)-amine are dissolved in 0.3 mL acetic acid and 0.3 mL hydrobromic acid (33% in acetic acid) and stirred at 80 °C for 72h. Then the solvents are removed. The mixture of starting material and desired product can be separated by HPLC (20 to 100% CH3CN/H20 (6'), 100% CH3CN (1.5'), 100 to 20% CH3CN/H20 (0.5'): product elutes after 4.5'). MS(ES+): 274 (M+1).
Example 24: (4-BenzoM ,2,51oxadiazol-5-vl-3-methox\^phenvl)-dimethyl-amine
200 mg (0.8 mmol) of (4-benzo[1,2,5]oxadiazol-5-yl-3-methoxy-phenyl)-methyl-arnine are stirred at 0 to 5 °C in 5 mL of DMF, then over 1 minute treated with 1 mL NaHMDS-solution (1.0 M, 1.25 eq.) and stirred another minute. Then, 0.5 mL (7.8 mmol, 10 eq.) of methyliodide is added and stirred 2 minutes under warming to rt. Then, the mixture is extracted with ethyl acetate/aqueous NaHC03 , the combined organic layers dried with sodium sulfate and concentrated. This yields the desired product as a reddish-yellow solid.
1H-NMR (CD3OD, 400 MKz): delta (ppm) = 7.80-7.84 (m, 2Harom); 7.36 (d, Harom); 6.50 (d, Harom); 6.45 (in, Harom); 3.90 (s, MeO); 3.08 (s, 2Me).
Example 25: 2-Benzof1.2 140 mg (0.52 mmol) of (4-benzo[1,2,5]oxadiazol-5-yl-3-methoxy-phenyl)-dimethyl-amine are stirred at -10 to 0 °C in 1.7 mL of CH2CI2l then over 5 minutes treated with 1.7 mL AIBr3 (1.0 M solution in CH2Br2, 3.3 eq.) and stirred another 19 h under warming to rt. Then, the mixture is extracted with brine/ethyl acetate, the combined organic layers dried with sodium sulfate and concentrated. The crude product is column chromatographed with ethyl acetate/hexanes 1:4 to yield after evaporation of the product-containing fractions the desired product as a red solid.

1H-NMR (CD3OD, 400 MHz): delta (ppm) = 7.90-7.94 (m, 2Harom); 7.80 (d, Harom); 6.43 (d, Harom); 6.38 (m, Harom); 4.00 (s, 2Me).
Example 26:
Staining ofAPP23 mouse and human Alzheimer disease (AD) brain sections using an
agent of the invention or Thioflavine S.
Four-micrometer thick paraffin sections from an APP23 mouse at 26 months of age are deparaffinized in xylene and rehydrated. 10 mg of the compound are dissolved in 1 mL DMSO and diluted with deionized water 1:10. This staining solution is applied on sections for about 20 min. Section background is cleared by washing with 95% ethanol. Finally sections are dehydrated in 99% ethanol, cleared in xylene and mounted with Vectashield1m. Sections are investigated using fluorescence microscopy with the following filter combination: Excitation 450-490 nm, emission 510 nm. Twenty micrometer thick cryotom sections from a AD brain cortex are air dried and fixated in 4% PFA for 5 min. After washing in tap water sections are stained either with Thioflavine S or with the compound for 5 min and further processed as described above. The compound is dissolved in DMSO and diluted to a final concentration of 0.01 % with 50% Ethanol, Thioflavine S is dissolved in 50% Ethanol, final concentration is 0.01 %.
Results:
(These results do not apply to the compounds of Examples 4, 5, 11, 12 and 21, which are
not fluorescent)
1) Staining of APP23 mice brain sections
The agents of the invention strongly stain amyloid deposits and vascular deposits in brain sections ofAPP23 mice.
2) Staining of human AD brain sections:
Brain sections taken from frontal cortex of AD patients are stained with the agents of the invention, and the results compared with a Thioflavine S stain. The agents of the invention intensely and selectively stain amyloid deposits.

Claims
1. A compound of formula I

wherein X is O or S, R^ is 5-(2-fluoro^thylamino)-thiazol-2-yI, 5-(2-™F-ethylamino)-thiazol-2-yl or a group of formula (a)

wherein Y is CH or N, R2 is NHCH3, NH11CH3, N(CH3)11CH3, N(CH3)2| N(11CHs)2l NH(CH2)nF, NH(CH2)n16F, N(CH3)-(CH2)nF, N(CH3)-(CH2)n18F, 0-(CH2)nF, O-(CH2)n18F, CONH(CH2)nF or CONH(CH2)nt3F (n being in each case 2 to 4) and R3 is hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form.
2. A process for the production of a compound of formula I as defined in claim 1 and its salts, comprising the steps of
a) for the production of a compound of formula I which contains no 11C or 18F atom, reacting a compound of formula ii

wherein X is as defined in claim 1 and Hal is CI, Br or I, with 5-(2-fluoro-ethylamino)thiazolyi-2-boronic acid or a compound of formula III

wherein Y and R3 are as defined above and R'2 is a group R2 as defined above which contains no 11C or 1BF atom, or
b) for the production of a compound of formula I wherein R, is 5-(2-18F-ethylamino)-thiazoI-2-yl, reacting a compound of formula I wherein R-i is 5-(2-mesyloxy-ethylamino)-thiazoI-2-yl or 5-(2-tosyloxy^thylamino)-thiazoI-2-yI with 18Fe, or
c) for the production of a compound of formula I wherein R2 is NH11CH3, N(CH3)11CH3 or N(11CH3)2, reacting a compound of formula I wherein R2 is NH2 or NHCH3 with 11CH3I, or
d) for the production of a compound of formula I wherein R2 is NH(CH2)n18F, N(CH3)-(CH2)n16F, 0-(CH2)n16F or CONH(CH2)n1BF, reacting a compound of formula I wherein R2 is, respectively, NH(CH2)nOTs or NH(CH2)nOMs, N(CH3)-(CH2)nOTs or N(CH3)-(CH2)n-OMs, O-(CH2)nOTs or 0-(CH2)n-OMs, or CONH(CH2)nOTs or ONH(CH2)nOMs, with 1sFe,
and recovering the resulting compound of formula I in free base form or in form of an acid addition salt
3. A composition for labeling histopathological structures in vitro or in vivo, comprising a compound of formula I as defined in claim 1, in free base or acid addition salt form.
4. A method for labeling histopathological structures in vitro or in vivo, comprising contacting brain tissue with a compound of formula I as defined in claim 1, in free base or acid addition salt form.
5. A method according to claim 4, for labeling E-amyloid deposits.

6. A method according to ciaim 4 or 5, comprising administering the compound of formula
i to a patient.
7. A method according to any of claims 4 to 6, comprising the further step of determining whether the compound of formula I labeled the target structure.
8. A method according to claim 7, comprising observing the target structure labeled with a non-radioactive compound of formula I, using fluorescence microscopy.
9. A method according to claim 7, comprising observing the target structure labeled with a radioactive compound of formula I, using positron emission tomography (PET).
10. A method according to any one of claims 4 to 7, and 9 for diagnosing Alzheimer's disease.
11. A method according to claim 10, for monitoring the effectiveness of a therapeutic-treatment of Alzheimer's disease.
12. A method according to any of claims 4, 5, 7 and 8, for detecting histopathoiogical hallmarks of Alzheimer's disease.
13. The use of a compound of formula I according to claim 1 for the manufacture of a preparation for the treatment or diagnosis of Alzheimer's disease.
14. A package comprising a compound of formula I wherein R2 is NH2 or NHCHS together with instructions for the production of a compound of formula I wherein R2 is NH11CH3, N(CH3)11CH3 or N(11CH3)2 by reaction of the starting material with freshly prepared "CH3I.
15. A package comprising as starting material a compound of formula I wherein R2 is NH(CH2)nOTs, NH(CH2)nOMs, N(CH3KCH2)nOTs, N(CH3)-(CH2)nOMs, O-(CH2)nOTs, 0-(CH2)rrOMs, CONH(CH2)nOTs or ONH(CH2)nOMs, wherein OMs corresponds to mesylate and OTs to tosylate, together with instructions for the production of a

compound of formula I wherein R2 is NH(CH2)n18F, N(CH3)-(CH2)n18F, 0-(CH2)n18F or CONH(CH2)n18F by a suitable reaction cascade of the starting material with 18F®.

Documents:

2503-chenp-2005 abstract granted.pdf

2503-chenp-2005 claims granted.pdf

2503-chenp-2005 description(complete) granted.pdf

2503-chenp-2005-abstract.pdf

2503-chenp-2005-claims.pdf

2503-chenp-2005-correspondnece-others.pdf

2503-chenp-2005-correspondnece-po.pdf

2503-chenp-2005-description(complete).pdf

2503-chenp-2005-form 1.pdf

2503-chenp-2005-form 3.pdf

2503-chenp-2005-form 5.pdf

2503-chenp-2005-form18.pdf

2503-chenp-2005-pct.pdf

« Previous Patent

Next Patent »

Patent Number

226030

Indian Patent Application Number

2503/CHENP/2005

PG Journal Number

02/2009

Publication Date

09-Jan-2009

Grant Date

04-Dec-2008

Date of Filing

03-Oct-2005

Name of Patentee

NOVARTIS AG

Applicant Address

LICHTSTRASSE 35, CH-4056 BASEL,

Inventors:

#	Inventor's Name	Inventor's Address
1	AUBERSON, YVES	MAIENGASSE 4, CH-4123 ALLSCHWIL,
2	HINTERMANN, SAMUEL	KLINGELBERGSTRASSE 93, CH-4056 BASEL,
3	ZIMMERMANN, KASPAR	AM CHATZEBACH 4, CH-4104 OBERWIL BL,

PCT International Classification Number

C07D271/12

PCT International Application Number

PCT/EP04/03517

PCT International Filing date

2004-04-02

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	0307855.7	2003-04-04	U.K.